Loading…
Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies
Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs ar...
Saved in:
Published in: | BioMed research international 2013-01, Vol.2013 (2013), p.1-9 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863 |
---|---|
cites | cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863 |
container_end_page | 9 |
container_issue | 2013 |
container_start_page | 1 |
container_title | BioMed research international |
container_volume | 2013 |
creator | Cherwonogrodzky, John W. Yu, Justin Lillico, Dustin Hu, Charles Chen Chau, Damon Yin, Junfei Hu, Wei-Gang Negrych, Laurel M. |
description | Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes. |
doi_str_mv | 10.1155/2013/471346 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3591125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373372879</galeid><sourcerecordid>A373372879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</originalsourceid><addsrcrecordid>eNqNkVtLHDEYhoMoKupV72XBG2kZ_XKYZHIjLNuDBXug2OuQyWE3Mpusk9kW--vNMHaxd81NQr6Hh5fvRegNhiuM6_qaAKbXTGDK-B46JhSzimOG93dvSo_QWc4PUE6DOUh-iI4IZQ3DBI7R_SJFn_q1HkKK1Xu3cdG6OMxuw3JVzb0PMQxPs-9pGD9_BBNi9dVth1534U-Iy9mXFJPpUtTdbB6H0CYbXD5FB1532Z293Cfo58cP94vb6u7bp8-L-V1laoChYgCGtlADl1YDBm8bLS0nZaiNEIJbRomT0gpg3tNWSNZqJ71vmSd1w-kJupm8m227dtaUjCWY2vRhrfsnlXRQ_05iWKll-qVoLTEmdRFcvgj69Lh1eVDrkI3rOh1d2maFGWc1MNLIgl5M6FJ3ToWytGI0I67mVFAqSCNG6t1EmT7l3Du_C4NBjYWpsTA1FVbo89f5d-zfegrwdgJWIVr9O_yfzRXEef0KBkZLuGf13qbH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464504289</pqid></control><display><type>article</type><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M.</creator><contributor>Byrne, Barry J.</contributor><creatorcontrib>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M. ; Byrne, Barry J.</creatorcontrib><description>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2013/471346</identifier><identifier>PMID: 23484120</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Animals ; Antibodies, Monoclonal, Murine-Derived - immunology ; Antibodies, Monoclonal, Murine-Derived - pharmacology ; Antibodies, Neutralizing - immunology ; Antibodies, Neutralizing - pharmacology ; Antibody Affinity ; Antidotes ; Antitoxins - immunology ; Antitoxins - pharmacology ; Drug therapy ; Epitopes - immunology ; Female ; Health aspects ; Mice ; Mice, Inbred BALB C ; Monoclonal antibodies ; Poisoning ; Protein Structure, Tertiary ; Ricin ; Ricin - immunology ; Ricin - toxicity</subject><ispartof>BioMed research international, 2013-01, Vol.2013 (2013), p.1-9</ispartof><rights>Copyright © 2013 Wei-Gang Hu et al.</rights><rights>COPYRIGHT 2013 John Wiley & Sons, Inc.</rights><rights>Copyright © 2013 Wei-Gang Hu et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</citedby><cites>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925,37013</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23484120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Byrne, Barry J.</contributor><creatorcontrib>Cherwonogrodzky, John W.</creatorcontrib><creatorcontrib>Yu, Justin</creatorcontrib><creatorcontrib>Lillico, Dustin</creatorcontrib><creatorcontrib>Hu, Charles Chen</creatorcontrib><creatorcontrib>Chau, Damon</creatorcontrib><creatorcontrib>Yin, Junfei</creatorcontrib><creatorcontrib>Hu, Wei-Gang</creatorcontrib><creatorcontrib>Negrych, Laurel M.</creatorcontrib><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</description><subject>Animals</subject><subject>Antibodies, Monoclonal, Murine-Derived - immunology</subject><subject>Antibodies, Monoclonal, Murine-Derived - pharmacology</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Neutralizing - pharmacology</subject><subject>Antibody Affinity</subject><subject>Antidotes</subject><subject>Antitoxins - immunology</subject><subject>Antitoxins - pharmacology</subject><subject>Drug therapy</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monoclonal antibodies</subject><subject>Poisoning</subject><subject>Protein Structure, Tertiary</subject><subject>Ricin</subject><subject>Ricin - immunology</subject><subject>Ricin - toxicity</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNkVtLHDEYhoMoKupV72XBG2kZ_XKYZHIjLNuDBXug2OuQyWE3Mpusk9kW--vNMHaxd81NQr6Hh5fvRegNhiuM6_qaAKbXTGDK-B46JhSzimOG93dvSo_QWc4PUE6DOUh-iI4IZQ3DBI7R_SJFn_q1HkKK1Xu3cdG6OMxuw3JVzb0PMQxPs-9pGD9_BBNi9dVth1534U-Iy9mXFJPpUtTdbB6H0CYbXD5FB1532Z293Cfo58cP94vb6u7bp8-L-V1laoChYgCGtlADl1YDBm8bLS0nZaiNEIJbRomT0gpg3tNWSNZqJ71vmSd1w-kJupm8m227dtaUjCWY2vRhrfsnlXRQ_05iWKll-qVoLTEmdRFcvgj69Lh1eVDrkI3rOh1d2maFGWc1MNLIgl5M6FJ3ToWytGI0I67mVFAqSCNG6t1EmT7l3Du_C4NBjYWpsTA1FVbo89f5d-zfegrwdgJWIVr9O_yfzRXEef0KBkZLuGf13qbH</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Cherwonogrodzky, John W.</creator><creator>Yu, Justin</creator><creator>Lillico, Dustin</creator><creator>Hu, Charles Chen</creator><creator>Chau, Damon</creator><creator>Yin, Junfei</creator><creator>Hu, Wei-Gang</creator><creator>Negrych, Laurel M.</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><author>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal, Murine-Derived - immunology</topic><topic>Antibodies, Monoclonal, Murine-Derived - pharmacology</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Neutralizing - pharmacology</topic><topic>Antibody Affinity</topic><topic>Antidotes</topic><topic>Antitoxins - immunology</topic><topic>Antitoxins - pharmacology</topic><topic>Drug therapy</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monoclonal antibodies</topic><topic>Poisoning</topic><topic>Protein Structure, Tertiary</topic><topic>Ricin</topic><topic>Ricin - immunology</topic><topic>Ricin - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cherwonogrodzky, John W.</creatorcontrib><creatorcontrib>Yu, Justin</creatorcontrib><creatorcontrib>Lillico, Dustin</creatorcontrib><creatorcontrib>Hu, Charles Chen</creatorcontrib><creatorcontrib>Chau, Damon</creatorcontrib><creatorcontrib>Yin, Junfei</creatorcontrib><creatorcontrib>Hu, Wei-Gang</creatorcontrib><creatorcontrib>Negrych, Laurel M.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cherwonogrodzky, John W.</au><au>Yu, Justin</au><au>Lillico, Dustin</au><au>Hu, Charles Chen</au><au>Chau, Damon</au><au>Yin, Junfei</au><au>Hu, Wei-Gang</au><au>Negrych, Laurel M.</au><au>Byrne, Barry J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>23484120</pmid><doi>10.1155/2013/471346</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2314-6133 |
ispartof | BioMed research international, 2013-01, Vol.2013 (2013), p.1-9 |
issn | 2314-6133 2314-6141 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3591125 |
source | Wiley Online Library Open Access; Publicly Available Content Database |
subjects | Animals Antibodies, Monoclonal, Murine-Derived - immunology Antibodies, Monoclonal, Murine-Derived - pharmacology Antibodies, Neutralizing - immunology Antibodies, Neutralizing - pharmacology Antibody Affinity Antidotes Antitoxins - immunology Antitoxins - pharmacology Drug therapy Epitopes - immunology Female Health aspects Mice Mice, Inbred BALB C Monoclonal antibodies Poisoning Protein Structure, Tertiary Ricin Ricin - immunology Ricin - toxicity |
title | Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A13%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conformation-Dependent%20High-Affinity%20Potent%20Ricin-Neutralizing%20Monoclonal%20Antibodies&rft.jtitle=BioMed%20research%20international&rft.au=Cherwonogrodzky,%20John%20W.&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2013/471346&rft_dat=%3Cgale_pubme%3EA373372879%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1464504289&rft_id=info:pmid/23484120&rft_galeid=A373372879&rfr_iscdi=true |